Site advantages

FMP-Labor

Excellent research, maximum and specialized health care, a knowledge-based economy and multifaceted education and training in the healthcare industry are distinguishing features of Buch. With its clear focus on biomedicine, the health location has outstanding innovation and growth potential. Berlin-Buch has been designated as a premier location for future development in the innovation strategy of the capital city region.

There basic and clinical researchers from academia and non-university institutions are closely interlinked, as are the hospitals, and biotech companies and medical technology companies. Altogether, as key employers in Berlin-Buch, they employ nearly 6,500 people in the health sector. In addition, the health location Berlin-Buch generates an annual value of 320 million euros plus an additional 227 million euros in demand effects in Berlin. As a consequence, over 7,500 jobs have been created in Berlin, resulting in tax revenues for Berlin of 13 million euros per year *.

Thanks to the public funding by the Federal Government and the State of Berlin amounting to 624 million euros**, the research campus in Berlin-Buch has an excellent scientific infrastructure, state-of-the art technology platforms and a biotech park with more than 60 companies. The renown of the science and health location attracts world-class scientists and is a magnet for new companies and enterprises.

This has meant that in recent years substantial private investments of 827 million euros have been invested in the region**. The HELIOS Kliniken group has established a maximum-care hospital in Buch and has invested 336 million euros** for this purpose. Thanks to the commitment of companies such as UKB Denkmal AG, COMBAG AG, Ludwig Hoffmann Quartier Objektgesellschaft mbH & Co. KG and the Widerker Group, historic hospital properties have been converted into attractive residential parks. Moreover, a shopping mall, the Schlosspark-Passage has been built in the center of Buch. Companies of the BiotechPark have attracted private investments, including hundreds of millions of euros in venture capital.


*Source: DIW Study “Gesundheitsstandort Berlin-Buch: Was ist der wirtschaftliche Nutzen für Berlin?“ [Health location Berlin-Buch: What is the economic benefit for Berlin?], 2008
**Up to and including 2015


Nine good reasons for settling on Campus Berlin-Buch

  • Premier capital city location
  • Immediate availability of space
  • Specialized labor force
  • Excellent research centers and hospitals on the campus
  • Attractive rental terms
  • Staff development and in-service training on-site
  • Vibrant and cosmopolitan Campus community
  • Interdisciplinary networks and platforms with uncomplicated access
  • Increasing attractiveness of Berlin-Buch as place to live for Campus employees

News Buch Berlin

Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Contract Development and Manufacturing Services

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) has received from the Berlin City Government a 66-year long-term lease for an industrial property with 53,000 square feet (...

more ...

Lighting up tumor cells

MDC PhD student Matthias Jürgen Schmitt is being honored with the Curt Meyer Memorial Prize of the Berlin Cancer Society for his achievements in cancer research. He employs molecular reporters to inve...

more ...

Nantes University Hospital Doses First Patients with Eckert & Ziegler’s Novel Ga-68 Imaging Agent PENTIXAFOR

PENTIXAFOR is an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas. The Ga-68 based radio-diagnostic promises to significantly improve the patie...

more ...

Events Buch Berlin

08.11.2021, 09:00
Weiterbildungskurs: Fachkraft für Molekularbiologie (TÜV) vom 8. - 19. November 2021

Das 11-tägige Intensiv-Seminar vermittelt Grundlagenwissen zu den wichtigsten Labormethoden der modernen Molekularbiologie und vermittelt Einblicke in die klinische Forschung. Nutzen Sie auch die Gele...

more ...

09.11.2021, 16:00
Vortrag: "SARS-Cov-2-Forschung: Zellveränderungen bei Infektion und daraus entstehende unterschiedliche Krankheitsverläufe"

Referent: Dr. Emanuel Wyler, Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC)/BIMSB

more ...

22.11.2021, 15:00
VORLESUNGSREIHE "NEUE WEGE IN DER BIOMEDIZIN": Neues aus der Hirnforschung

Themen sind Esssörungen und Multiple Sklerose

more ...

This website is supported by: